Mabs vs. TKIs: Two Paths to Cancer Targeting -White PaperKalorama InformationNovember 1, 2011 4 Pages - SKU: KLI6658974 |
| Monoclonal antibodies (mAbs) Tyrosine kinase inhibitors (TKIs) represent two types of cancer treatment. Both involve biological processes but attack the problem in different ways. One limits the bodies cell growth, the other helps the immune system target cancer cells. From a market perspective there has been an interesting trend as revenues for TKI products such as Gleevec have continued to grow. This White Paper from Kalorama Information describes this trend. Information from the Kalorama Report KLI6501843: Cancer Therapeutics was used in this White Paper. |
Related Markets
Oncology/Hematology Reports
- Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
- Commercializing Biomarkers in Therapeutic and Diagnostic Applications
- Hematological Cancer Therapies
